The Essential Role of IL-17 as the Pathogenetic Link between Psoriasis and Metabolic-Associated Fatty Liver Disease
Olveira, Antonio (Hospital Universitario La Paz (Madrid))
Augustin Recio, Salvador (Hospital Universitari Vall d'Hebron)
Benlloch, Salvador (Hospital Arnau de Vilanova (València))
Ampuero, Javier (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia))
Suárez-Pérez, Jorge Alonso (Hospital Universitario Virgen de la Victoria (Màlaga, Andalusia))
Armesto, Susana (Hospital Universitario Marqués de Valdecilla (Santander, Cantabria))
Vilarrasa-Rull, Eva (Institut d'Investigació Biomèdica Sant Pau)
Belinchón, Isabel (Universidad Miguel Hernández de Elche)
Herranz, Pedro (Hospital Universitario La Paz (Madrid))
Crespo García, Javier (Hospital Universitario Marqués de Valdecilla (Santander, Cantabria))
Guimerá, Francisco (Hospital Universitario de Canarias (La Laguna))
Gómez-Labrador, Lara (Novartis Farmacéutica (Madrid))
Martín, Víctor (Novartis Farmacéutica (Madrid))
Carrascosa, José Manuel (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Universitat Autònoma de Barcelona

Date:	2023
Abstract:	Interleukin 17 (IL-17) is an effector cytokine that plays a key role in the pathogenesis of both psoriasis and metabolic-associated fatty liver disease (MAFLD), a condition that is more prevalent and severe in patients with psoriasis. In liver inflammation, IL-17 is mainly produced by CD4+ T (TH17) and CD8+ T cells (Tc17), although numerous other cells (macrophages, natural killer cells, neutrophils and Tγδ cells) also contribute to the production of IL-17. In hepatocytes, IL-17 mediates systemic inflammation and the recruitment of inflammatory cells to the liver, and it is also implicated in the development of fibrosis and insulin resistance. IL-17 levels have been correlated with progression from MAFLD to steatohepatitis, cirrhosis, and even hepatocellular carcinoma. Clinical trials have shown that inhibiting IL-17A in patients with psoriasis could potentially contribute to the improvement of metabolic and liver parameters. A better understanding of the key factors involved in the pathogenesis of these chronic inflammatory processes could potentially lead to more efficient treatment for both psoriasis and MAFLD, and help to develop holistic strategies to improve the management of these patients.
Rights:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Language:	Anglès
Document:	Article ; recerca ; Versió publicada
Subject:	Psoriasis ; Metabolic-associated fatty liver disease ; MAFLD ; IL-17 ; IL-17A
Published in:	Life, Vol. 13 (february 2023) , ISSN 2075-1729

DOI: 10.3390/life13020419
PMID: 36836776

13 p, 1.2 MB

The record appears in these collections:
Articles > Research articles
Articles > Published articles